EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology

被引：11
|
作者：
Graziano, Paolo [1 ]
de Marinis, Filippo [1 ]
Gori, Bruno [1 ]
Gasbarra, Rita [1 ]
Migliorino, Rita [1 ]
De Santis, Stefano [1 ]
Pelosi, Giuseppe [2 ,3 ]
Leone, Alvaro [1 ]
机构：
[1] San Camillo Forlanini Hosp, Rome, Italy
[2] Fdn Ist Ricovero & Cura Carattere Sci, Ist Tumori, Milan, Italy
[3] Univ Milan, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 31期
关键词：
LUNG-CANCER; GEFITINIB; ERLOTINIB; PATIENT;
D O I：
10.1200/JCO.2013.49.5697
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E115 / E118
页数：4
相关论文
共 50 条
  • [31] Utility of T790M plasma and tissue biopsy testing in EGFR mutated non-small-cell lung cancer patients
    Preda, E.
    Shamash, J.
    Tarver, K.
    Ball, S.
    LUNG CANCER, 2020, 139 : S61 - S62
  • [32] Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer
    Singh, Pankaj Kumar
    Silakari, Om
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (05) : 469 - 483
  • [33] An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
    Wang, Jingyi
    Wu, Lin
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 647 - 652
  • [34] Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR
    Hwang, Ki-Eun
    Kwon, Su-Jin
    Kim, Young-Suk
    Park, Do-Sim
    Kim, Byoung-Ryun
    Yoon, Kwon-Ha
    Jeong, Eun-Taik
    Kim, Hak-Ryul
    EXPERIMENTAL CELL RESEARCH, 2014, 323 (02) : 288 - 296
  • [35] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [36] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [37] AfatinibAn additional T790M point mutation with transformation to squamous cell carcinoma: case report
    Reactions Weekly, 2017, 1669 (1) : 18 - 18
  • [38] Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
    Peng, MuYun
    Wen, QiuYuan
    Wu, Xia
    Yu, FengLei
    Liu, WenLiang
    THORACIC CANCER, 2020, 11 (09) : 2704 - 2708
  • [39] EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
    Sonoda, Tomoaki
    Nishikawa, Shingo
    Sakakibara, Rie
    Saiki, Masafumi
    Ariyasu, Ryo
    Koyama, Junji
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Ohyanagi, Fumiyoshi
    Ninomiya, Hironori
    Ishikawa, Yuichi
    Nishio, Makoto
    RESPIRATORY MEDICINE CASE REPORTS, 2018, 24 : 19 - 21
  • [40] Clinicopathological Characteristics of Non-small Cell Lung Cancer Patients With Primary Concomitant EGFR T790M Mutation
    Li, Hang
    Wang, Rui
    Hu, Haichuan
    Pan, Yunjian
    Wang, Lei
    Zhang, Yang
    Sun, Yihua
    Chen, Haiquan
    CHEST, 2014, 145 (03)
12345